scholarly journals Social inequalities contribute to racial/ethnic disparities in depressive symptomology among men who have sex with men

Author(s):  
Benjamin W. Barrett ◽  
Alison G. Abraham ◽  
Lorraine T. Dean ◽  
Michael W. Plankey ◽  
M. Reuel Friedman ◽  
...  
2018 ◽  
Vol 108 (S4) ◽  
pp. S266-S273 ◽  
Author(s):  
Patrick S. Sullivan ◽  
David W. Purcell ◽  
Jeremy A. Grey ◽  
Kyle T. Bernstein ◽  
Thomas L. Gift ◽  
...  

2019 ◽  
Vol 68 (37) ◽  
pp. 801-806 ◽  
Author(s):  
Dafna Kanny ◽  
William L. Jeffries ◽  
Johanna Chapin-Bardales ◽  
Paul Denning ◽  
Susan Cha ◽  
...  

2010 ◽  
Vol 87 (2) ◽  
pp. 318-323 ◽  
Author(s):  
Robert Garofalo ◽  
Brian Mustanski ◽  
Amy Johnson ◽  
Erin Emerson

2021 ◽  
Author(s):  
Anthony Nguyen ◽  
Emmanuel Fulgence Drabo ◽  
Wendy Garland ◽  
Corrina Moucheraud ◽  
Ian W Holloway ◽  
...  

ABSTRACTBackgroundRacial and ethnic minority men who have sex with men (MSM) are disproportionately affected by HIV/AIDS in Los Angeles County (LAC), an important epicenter in the battle to end HIV.ObjectiveTo examine tradeoffs between effectiveness and equality of PrEP allocation strategies among different racial and ethnic groups of MSM in LAC.Design, Setting, and PopulationWe developed a microsimulation model of HIV among MSM in LAC using county epidemic surveillance and survey data to capture demographic trends and subgroup-specific partnership patterns, disease progression, patterns of PrEP use, and patterns for viral suppression.InterventionWe simulated interventions where an additional 3000, 6000, or 9000 PrEP prescriptions are provided annually in addition to current levels, following different allocation scenarios to each racial/ethnic group (Black, Hispanic, or White).MeasurementsWe estimated cumulative infections averted and measures of equality, after 15 years (2021-2035), relative to base case (no intervention).ResultsOf the policies evaluated, targeting PrEP preferentially to Black individuals would result in the largest reductions in incidence and disparities. This outcome was robust to different partnership preference assumptions, though the magnitude of impact differs.LimitationsWe limit analysis to MSM, who bear the majority of HIV/AIDS burden in LAC. We do not consider transmission via injection drug use or mother-to-child transmission, nor do we capture individual network transmission effects. We assume no improvements in the prevention-diagnosis-treatment cascade besides increased PrEP use.ConclusionsWe find there is little trade-off between effectiveness and equality of outcome when choosing groups to target for PrEP in LAC – by focusing on MSM with the highest HIV incidence (Black), we can reduce both overall infections and racial/ethnic disparities.


AIDS Care ◽  
2016 ◽  
Vol 29 (3) ◽  
pp. 311-318 ◽  
Author(s):  
Diana M. Sheehan ◽  
Mary Jo Trepka ◽  
Kristopher P. Fennie ◽  
Guillermo Prado ◽  
Gladys Ibanez ◽  
...  

2008 ◽  
Vol 13 (4) ◽  
pp. 716-723 ◽  
Author(s):  
Spencer Lieb ◽  
Paul Arons ◽  
Daniel R. Thompson ◽  
Alberto M. Santana ◽  
Thomas M. Liberti ◽  
...  

2012 ◽  
Author(s):  
J. Liang ◽  
X. Xu ◽  
A. R. Quinones ◽  
J. M. Bennett ◽  
W. Ye

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1489-P
Author(s):  
SHARON SHAYDAH ◽  
GIUSEPPINA IMPERATORE ◽  
CARLA MERCADO ◽  
KAI M. BULLARD ◽  
STEPHEN R. BENOIT

2017 ◽  
Vol 35 (1) ◽  
pp. 86-95 ◽  
Author(s):  
Albert J. Farias ◽  
Xianglin L. Du

Purpose Previous studies suggest that adherence to adjuvant endocrine therapy (AET) for patients with breast cancer is suboptimal, especially among minorities, and is associated with out-of-pocket medication costs. This study aimed to determine whether there are racial/ethnic differences in 1-year adherence to AET and whether out-of-pocket costs explain the racial/ethnic disparities in adherence. Methods This retrospective cohort study used the SEER-Medicare linked database to identify patients ≥ 65 years of age with hormone receptor–positive breast cancer who were enrolled in Medicare Part D from 2007 to 2009. The cohort included non-Hispanic whites, blacks, Hispanics, and Asians. Out-of-pocket costs for AET medications were standardized for a 30-day supply. Adherence to tamoxifen, aromatase inhibitors (AIs), and overall AET (tamoxifen or AIs) was assessed using the medication possession ratio (≥ 80%) during the 12-month period. Results Of 8,688 patients, 3,197 (36.8%) were nonadherent to AET. Out-of-pocket costs for AET medication were associated with lower adjusted odds of adherence for all four cost categories compared with the lowest category of ≤ $2.65 ( P < .01). In the univariable analysis, Hispanics had higher odds of adherence to any AET at initiation (OR, 1.30; 95% CI, 1.07 to 1.57), and blacks had higher odds of adherence to AIs at initiation (OR, 1.27; 95% CI, 1.04 to 1.54) compared with non-Hispanic whites. After adjusting for copayments, poverty status, and comorbidities, the association was no longer significant for Hispanics (OR, 0.95; 95% CI, 0.78 to 1.17) or blacks (OR, 0.96; 95% CI, 0.77 to 1.19). Blacks had significantly lower adjusted odds of adherence than non-Hispanic whites when they initiated AET therapy with tamoxifen (OR, 0.54; 95% CI, 0.31 to 0.93) after adjusting for socioeconomic, clinic, and prognostic factors. Conclusion Racial/ethnic disparities in AET adherence were largely explained by women's differences in socioeconomic status and out-of-pocket medication costs.


Sign in / Sign up

Export Citation Format

Share Document